Kewei Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kewei Xu has a total of 212 co-authors. Here are the top co-authors by number of shared publications:
Cong Lai
Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
31 shared publications- Cheng Liu
Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
26 shared publications Jintao Hu
Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
18 shared publicationsCheng Liu
Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
17 shared publicationsJuanyi Shi
Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510000, Guangdong, China
16 shared publicationsZhuohang Li
Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510000, Guangdong, China
16 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by Springer Nature in npj Precision Oncology
Qiling formula targets CDK5R1 to suppress enzalutamide resistance in prostate cancer: integrating prognostic modeling and function validation
- 15 October 2026
- Published by Springer Nature in npj Precision Oncology
Open AccessQiling formula targets CDK5R1 to suppress enzalutamide resistance in prostate cancer: integrating prognostic modeling and function validation
- Open Access
- 27 September 2026
- Published by Wiley in Advanced Science
Dual Compartmentalization of GSTA4 Suppresses Ferroptosis to Drive Antiandrogen Resistance in Prostate Cancer
Resistance to second‐generation antiandrogens poses a major therapeutic challenge in castration‐resistant prostate cancer (CRPC). While ferroptosis evasion has been implicated in treatment failure, the key molecular determinants driving this evasive process are poorly understood. Using integrated multi‐omics analyses of resistant models and patient specimens, we identify glutathione S‐transferase alpha 4 (GSTA4) as a pivotal ferroptosis suppressor that is associated with adverse clinical outcomes and drives antiandrogen resistance via a dual compartmentalization mechanism. Our data demonstrate that GSTA4 not only detoxifies the lipid peroxidation product 4‐hydroxynonenal in the cytosol but also translocates to the mitochondria under ferroptotic stress. GSTA4 interacts with PGAM5 to prevent the dephosphorylation of Drp1 at Ser637, thereby maintaining mitochondrial fitness and suppressing ferroptosis. This spatially coordinated defense program is crucial for antiandrogen resistance, as GSTA4 knockdown sensitizes tumors to antiandrogen therapy. Virtual screening and surface plasmon resonance assays identify metformin as a candidate GSTA4 inhibitor. Targeting GSTA4 with metformin restores ferroptosis sensitivity and reverses antiandrogen resistance both in vitro and in vivo. Our findings uncover a spatially coordinated anti‐ferroptotic mechanism underlying antiandrogen resistance and highlight targeting GSTA4 as a promising combination strategy for CRPC treatment.
- 27 September 2026
- Published by Wiley in Advanced Science
Open AccessDual Compartmentalization of GSTA4 Suppresses Ferroptosis to Drive Antiandrogen Resistance in Prostate Cancer
Resistance to second‐generation antiandrogens poses a major therapeutic challenge in castration‐resistant prostate cancer (CRPC). While ferroptosis evasion has been implicated in treatment failure, the key molecular determinants driving this evasive process are poorly understood. Using integrated multi‐omics analyses of resistant models and patient specimens, we identify glutathione S‐transferase alpha 4 (GSTA4) as a pivotal ferroptosis suppressor that is associated with adverse clinical outcomes and drives antiandrogen resistance via a dual compartmentalization mechanism. Our data demonstrate that GSTA4 not only detoxifies the lipid peroxidation product 4‐hydroxynonenal in the cytosol but also translocates to the mitochondria under ferroptotic stress. GSTA4 interacts with PGAM5 to prevent the dephosphorylation of Drp1 at Ser637, thereby maintaining mitochondrial fitness and suppressing ferroptosis. This spatially coordinated defense program is crucial for antiandrogen resistance, as GSTA4 knockdown sensitizes tumors to antiandrogen therapy. Virtual screening and surface plasmon resonance assays identify metformin as a candidate GSTA4 inhibitor. Targeting GSTA4 with metformin restores ferroptosis sensitivity and reverses antiandrogen resistance both in vitro and in vivo. Our findings uncover a spatially coordinated anti‐ferroptotic mechanism underlying antiandrogen resistance and highlight targeting GSTA4 as a promising combination strategy for CRPC treatment.
- Open Access
- 24 September 2026
- Published by Springer Nature in European Journal of Medical Research
Perioperative prediction of ideal postoperative recovery after kidney transplantation: a multicenter retrospective cohort study
- 24 September 2026
- Published by Springer Nature in European Journal of Medical Research
Open AccessPerioperative prediction of ideal postoperative recovery after kidney transplantation: a multicenter retrospective cohort study
- Open Access
- 28 August 2026
- Published by Springer Nature in Biomarker Research
- Vol. 14 (1) , 99
Evaluating global clinical trials and development trends of antibody-drug conjugates
- 28 August 2026
- Published by Springer Nature in Biomarker Research
- Vol. 14 (1) , 99
Open AccessEvaluating global clinical trials and development trends of antibody-drug conjugates
- 3 August 2026
- Published by Springer Nature in Oncogene
- Vol. 45 (38) , 4019-4036
Metabolic CRISPR screening identifies RPE as a key regulator of acquired enzalutamide resistance through FKBP5 destabilization in prostate cancer
- 3 August 2026
- Published by Springer Nature in Oncogene
- Vol. 45 (38) , 4019-4036
Metabolic CRISPR screening identifies RPE as a key regulator of acquired enzalutamide resistance through FKBP5 destabilization in prostate cancer
- 14 July 2026
- Published by Wolters Kluwer Health in Menopause
Premature menopause and risk of kidney stone disease: evidence from the UK biobank and National Health and Nutrition Examination Survey
Objective: Kidney stone disease (KSD) is a global health burden. Premature menopause (PM) may increase the likelihood of KSD, but the influence of hormone therapy (HT) and genetic predisposition is unclear. We examined the association between PM and KSD in two large cohorts and evaluated potential modification by HT and polygenic risk scores (PRS). Methods: We conducted cross-sectional analyses in 7,112 women from the National Health and Nutrition Examination Survey and 189,900 women from UK Biobank (UKB), with PM defined as menopause before age 40 years. Logistic regression estimated odds ratios (ORs) for prevalent KSD, and Cox models estimated hazard ratios (HRs) for incident KSD over a mean follow-up of ∼15 years in UKB. Sensitivity analyses and PRS stratification were performed to assess robustness and potential effect modification. Statistical analyses were conducted using R software. Results: In National Health and Nutrition Examination Survey (N = 7,112), KSD prevalence was higher in women with PM compared with women without PM (13.4% vs. 8.4%), with logistic regression showing 50% higher odds (OR: 1.54, 95% CI: 1.11-2.13). In the UKB baseline analysis (N = 189,900), PM was associated with higher odds of KSD (OR: 1.55, 95% CI: 1.32-1.83). In the prospective cohort (N = 188,282), women with PM had a 29%-55% higher hazard of incident KSD (HR: 1.29-1.55). Cumulative hazard curves showed early divergence ( P < 0.001). PRS analyses demonstrated increasing hazards of KSD with higher genetic predisposition (HR: 1.22-1.80). HT use partially attenuated, but did not eliminate, the elevated association. Conclusion: PM was consistently associated with KSD across two large cohorts. This association remained robust across multiple analytical approaches. Genetic predisposition was associated with higher hazards of KSD, whereas HT did not meaningfully modify these associations. These findings suggest a clinically relevant link that warrants further investigation in prospective and mechanistic studies.
- 14 July 2026
- Published by Wolters Kluwer Health in Menopause
Premature menopause and risk of kidney stone disease: evidence from the UK biobank and National Health and Nutrition Examination Survey
Objective: Kidney stone disease (KSD) is a global health burden. Premature menopause (PM) may increase the likelihood of KSD, but the influence of hormone therapy (HT) and genetic predisposition is unclear. We examined the association between PM and KSD in two large cohorts and evaluated potential modification by HT and polygenic risk scores (PRS). Methods: We conducted cross-sectional analyses in 7,112 women from the National Health and Nutrition Examination Survey and 189,900 women from UK Biobank (UKB), with PM defined as menopause before age 40 years. Logistic regression estimated odds ratios (ORs) for prevalent KSD, and Cox models estimated hazard ratios (HRs) for incident KSD over a mean follow-up of ∼15 years in UKB. Sensitivity analyses and PRS stratification were performed to assess robustness and potential effect modification. Statistical analyses were conducted using R software. Results: In National Health and Nutrition Examination Survey (N = 7,112), KSD prevalence was higher in women with PM compared with women without PM (13.4% vs. 8.4%), with logistic regression showing 50% higher odds (OR: 1.54, 95% CI: 1.11-2.13). In the UKB baseline analysis (N = 189,900), PM was associated with higher odds of KSD (OR: 1.55, 95% CI: 1.32-1.83). In the prospective cohort (N = 188,282), women with PM had a 29%-55% higher hazard of incident KSD (HR: 1.29-1.55). Cumulative hazard curves showed early divergence ( P < 0.001). PRS analyses demonstrated increasing hazards of KSD with higher genetic predisposition (HR: 1.22-1.80). HT use partially attenuated, but did not eliminate, the elevated association. Conclusion: PM was consistently associated with KSD across two large cohorts. This association remained robust across multiple analytical approaches. Genetic predisposition was associated with higher hazards of KSD, whereas HT did not meaningfully modify these associations. These findings suggest a clinically relevant link that warrants further investigation in prospective and mechanistic studies.
- Open Access
- 16 April 2026
- Published by Wiley in Advanced Science
- Vol. 13 (38) , e75290
ANXA2‐mediated Phagocytosis Generates AR + Macrophages to Confer Enzalutamide Resistance in Prostate Cancer
Resistance to second‐generation antiandrogens like enzalutamide (ENZ) in castration‐resistant prostate cancer (CRPC) is a major clinical challenge, yet the role in the tumor microenvironment remains poorly understood. This study identifies a unique AR‐positive tumor‐associated macrophages (AR + TAMs) subpopulation, enriched in ENZ‐resistant patients and correlated with poor prognosis, which acquires functional AR protein not through endogenous expression but via ANXA2‐dependent phagocytosis of tumor cells. The internalized AR protein translocates to the macrophage nucleus, directly binds the IL‐6 promoter to enhance its transcription and secretion. Macrophage‐derived IL‐6 subsequently activates the JAK2/STAT3 pathway in cancer cells, suppressing ENZ‐induced apoptosis and conferring therapeutic resistance. Genetic or pharmacological blockade of IL‐6 signaling restored ENZ sensitivity in vitro and in vivo, and combining an anti‐IL‐6 antibody with ENZ synergistically overcomes resistance in patient‐derived xenograft and orthotopic models. These findings reveal a novel phagocytosis‐mediated, paracrine mechanism of ENZ resistance orchestrated by AR + TAMs, challenging the tumor‐centric view of therapy failure and providing a strong rationale for co‐targeting the IL‐6 pathway to improve outcomes of AR‐directed therapy in CRPC.
- 16 April 2026
- Published by Wiley in Advanced Science
- Vol. 13 (38) , e75290
Open AccessANXA2‐mediated Phagocytosis Generates AR + Macrophages to Confer Enzalutamide Resistance in Prostate Cancer
Resistance to second‐generation antiandrogens like enzalutamide (ENZ) in castration‐resistant prostate cancer (CRPC) is a major clinical challenge, yet the role in the tumor microenvironment remains poorly understood. This study identifies a unique AR‐positive tumor‐associated macrophages (AR + TAMs) subpopulation, enriched in ENZ‐resistant patients and correlated with poor prognosis, which acquires functional AR protein not through endogenous expression but via ANXA2‐dependent phagocytosis of tumor cells. The internalized AR protein translocates to the macrophage nucleus, directly binds the IL‐6 promoter to enhance its transcription and secretion. Macrophage‐derived IL‐6 subsequently activates the JAK2/STAT3 pathway in cancer cells, suppressing ENZ‐induced apoptosis and conferring therapeutic resistance. Genetic or pharmacological blockade of IL‐6 signaling restored ENZ sensitivity in vitro and in vivo, and combining an anti‐IL‐6 antibody with ENZ synergistically overcomes resistance in patient‐derived xenograft and orthotopic models. These findings reveal a novel phagocytosis‐mediated, paracrine mechanism of ENZ resistance orchestrated by AR + TAMs, challenging the tumor‐centric view of therapy failure and providing a strong rationale for co‐targeting the IL‐6 pathway to improve outcomes of AR‐directed therapy in CRPC.
- Top Cited PapersOpen Access
Antibody–Drug Conjugates in Oncology: Principles, Clinical Development, and Future Directions
Antibody–drug conjugates (ADCs) have emerged as a major therapeutic modality in oncology, enabling the targeted delivery of highly potent cytotoxic agents while expanding the therapeutic window in solid tumors. Recent clinical successes across breast, lung, and genitourinary cancers have highlighted that ADC efficacy is governed not only by target expression, but also by the integrated optimization of antibody engineering, linker chemistry, payload selection, and tumor‐specific biology. In this review, we summarize the fundamental principles underpinning ADC design, including antibody format and Fc engineering, linker stability, payload classes, drug‐to‐antibody ratio optimization, and the bystander effect. We then discuss tumor antigen biology and target landscapes across solid tumors, with particular emphasis on how antigen density, heterogeneity, internalization kinetics, and intracellular trafficking shape clinical activity. Uro‐oncological malignancies—especially urothelial carcinoma—are presented as a clinically advanced and instructive paradigm for ADC development. Experience from these tumors illustrates both the opportunities and limitations of ADC therapy, including mechanisms of response and resistance, biomarker‐driven patient selection, rational combination strategies, and safety management in real‐world practice. Finally, we provide a forward‐looking perspective on next‐generation ADC development, highlighting emerging conjugation technologies, bispecific and conditionally activated ADCs, strategies to overcome resistance, and evolving clinical trial designs. By integrating engineering principles with tumor biology and clinical execution, this review aims to offer a translational framework to guide the future development and implementation of ADCs across oncology.
Top Cited PapersOpen AccessAntibody–Drug Conjugates in Oncology: Principles, Clinical Development, and Future Directions
Antibody–drug conjugates (ADCs) have emerged as a major therapeutic modality in oncology, enabling the targeted delivery of highly potent cytotoxic agents while expanding the therapeutic window in solid tumors. Recent clinical successes across breast, lung, and genitourinary cancers have highlighted that ADC efficacy is governed not only by target expression, but also by the integrated optimization of antibody engineering, linker chemistry, payload selection, and tumor‐specific biology. In this review, we summarize the fundamental principles underpinning ADC design, including antibody format and Fc engineering, linker stability, payload classes, drug‐to‐antibody ratio optimization, and the bystander effect. We then discuss tumor antigen biology and target landscapes across solid tumors, with particular emphasis on how antigen density, heterogeneity, internalization kinetics, and intracellular trafficking shape clinical activity. Uro‐oncological malignancies—especially urothelial carcinoma—are presented as a clinically advanced and instructive paradigm for ADC development. Experience from these tumors illustrates both the opportunities and limitations of ADC therapy, including mechanisms of response and resistance, biomarker‐driven patient selection, rational combination strategies, and safety management in real‐world practice. Finally, we provide a forward‐looking perspective on next‐generation ADC development, highlighting emerging conjugation technologies, bispecific and conditionally activated ADCs, strategies to overcome resistance, and evolving clinical trial designs. By integrating engineering principles with tumor biology and clinical execution, this review aims to offer a translational framework to guide the future development and implementation of ADCs across oncology.
- Open Access
- 19 March 2026
- Published by Springer Nature in Biomarker Research
- Vol. 14 (1) , 33
A global multidimensional analysis of the chimeric antigen receptor T-cell therapy clinical trial landscape and development trends
Chimeric antigen receptor T-cell (CAR-T) therapy has advanced significantly in oncology. To reveal the main trends affecting this field, we collected trial
- 19 March 2026
- Published by Springer Nature in Biomarker Research
- Vol. 14 (1) , 33
Open AccessA global multidimensional analysis of the chimeric antigen receptor T-cell therapy clinical trial landscape and development trends
Chimeric antigen receptor T-cell (CAR-T) therapy has advanced significantly in oncology. To reveal the main trends affecting this field, we collected trial
- Open Access
- 9 March 2026
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 26 (1)
Beyond valganciclovir: A meta-analysis of letermovir’s safety and efficacy in cytomegalovirus prophylaxis after solid organ transplantation
Cytomegalovirus (CMV) remains a major infectious cause of morbidity and graft dysfunction after solid organ transplantation (SOT). Valganciclovir (VGC) is
- 9 March 2026
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 26 (1)
Open AccessBeyond valganciclovir: A meta-analysis of letermovir’s safety and efficacy in cytomegalovirus prophylaxis after solid organ transplantation
Cytomegalovirus (CMV) remains a major infectious cause of morbidity and graft dysfunction after solid organ transplantation (SOT). Valganciclovir (VGC) is